Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Filings indexed 382 across all filing types
Latest filing 2024-08-27 Legal Proceedings Report
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Ouverture d'une procédure de liquidation judiciaire
Legal Proceedings Report Classification · 1% confidence The document is a press release ('Communiqué de presse') announcing a critical corporate event: the opening of judicial liquidation proceedings ('Ouverture d'une procédure de liquidation judiciaire') by the Commercial Court of Paris. This is a significant legal and financial event concerning the company's existence and structure, but it does not fit neatly into standard periodic reports (10-K, IR, ER) or specific transactional filings (DIV, SHA, CAP). It is not an AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DIRS, ER, SR, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. Since it is a formal announcement of a major legal/regulatory status change (liquidation) that doesn't fit the other specific categories, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements.
2024-08-27 French
Ajustement de la valeur nominale
Share Issue/Capital Change Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces an "Ajustement de la valeur nominale" (Par Value Adjustment) which results in a capital reduction due to losses. This action directly impacts the company's capital structure (reducing nominal value from 0.01 euro to 0.0002 euro and total capital). This falls under the category of updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate code is 'CAP' (Capital/Financing Update). The document is a formal announcement, not a full report, and the content is highly specific to capital structure modification.
2024-08-01 French
Point concernant l'accord de financement en obligations convertibles accordé par Global Tech Opportunities 13
Capital/Financing Update Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific event: the declaration of default under a convertible bond financing agreement with Global Tech Opportunities 13, and the potential termination of that agreement. It also mentions the upcoming hearing for judicial liquidation proceedings. This type of announcement, detailing financing events, debt issues, and potential capital structure impacts, fits best under 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a management discussion (MDA), but a specific update on financing arrangements and related legal/financial distress.
2024-07-18 French
Demande d'ouverture d'une procédure de liquidation judiciaire
Legal Proceedings Report Classification · 1% confidence The document is a press release ("Communiqué de presse") announcing that Pharnext SCA has filed a request for judicial liquidation proceedings ("Demande d'ouverture d'une procédure de liquidation judiciaire") with the Commercial Court of Paris. This is a significant legal and financial event concerning the company's operational status and solvency, which often triggers mandatory regulatory disclosure. While it relates to legal matters (LTR) and potentially capital structure (CAP), the core announcement is a critical, non-routine regulatory disclosure regarding the company's immediate future, which often falls under general regulatory announcements or specific legal/insolvency filings. Given the options, this type of critical, non-standard financial/legal event announcement that doesn't fit neatly into ER, 10-K, or standard IR/IP categories is best classified as a general Regulatory Filing (RNS), as it is a mandatory public disclosure of a major corporate event. Alternatively, since it explicitly discusses legal proceedings (the court filing for liquidation), LTR (Legal Proceedings Report) is a strong candidate. However, LTR usually implies an update on an existing lawsuit or regulatory action, whereas this is the initiation of a major insolvency procedure. Given the context of immediate, critical corporate status change announced via press release, RNS serves as the most appropriate catch-all for significant, non-standard regulatory news.
2024-07-15 French
Pharnext fait un point sur sa situation financière
Capital/Financing Update Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and dated July 10, 2024. It discusses the company's financial situation, specifically mentioning the inability to finance operations beyond July 15, 2024, and the intention to file for judicial liquidation ('déclaration de cessation des paiements auprès du Tribunal de Commerce et à solliciter l'ouverture d'une procédure de liquidation judiciaire'). This is a critical, time-sensitive announcement regarding the company's operational status and potential insolvency, which is typically disseminated via a press release or a general regulatory filing. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific corporate action announcement (like DIV, CAP, or DIRS), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings), as it is a significant, non-standard corporate update. Alternatively, given the severe financial distress and impending legal action, it could be considered a Legal Proceedings Report (LTR) or a Capital/Financing Update (CAP) regarding the failure of financing, but RNS is the best fit for a general 'financial situation update' press release that doesn't match a more specific category.
2024-07-10 French
Pharnext annonce la résiliation du contrat de financement accordé par Néovacs
Legal Proceedings Report Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces the early termination of a financing agreement with Néovacs, leading to a demand for early repayment of approximately €22 million. This content relates directly to the company's financing activities, debt obligations, and potential collateral enforcement. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it specifically details a material financing event.
2024-07-04 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.